Better target validation is a key driver of better productivity in drug discovery. The RNA-guided nucleases, exemplified by Cas9, represent a powerful new approach to understanding gene function and, in principle, to reveal the next generation of therapeutic targets. But how well does this technology work in practice?

Press Release updated: Oct 4, 2018 08:00 EDT

TORONTO, October 4, 2018 – Join our keynote speaker, Jon Moore, CSO at Horizon Discovery, for a live session on Tuesday, Oct. 23, 2018.

Horizon Discovery has used CRISPR/Cas9 to perform pooled screens of a 3,000-gene library, that includes protein and lipid kinases against a panel of some 35 cell lines predominantly derived from colon and lung cancers. The primary screens were followed up with ultra-deep pooled validation screens using a high-performance tracrRNA providing insights into the potential role of pharmacologically modulatable domains in target function. This exercise has identified some exciting new potential synthetic lethal targets for cancer therapies and also an independent dataset implying that some of the prominent RNA-interference derived targets under evaluation in the field will have only narrow therapeutic windows.

The key question now is, can we de-risk this new portfolio of targets to move forward in drug discovery on the best opportunities with some confidence that optimized small molecule inhibitors will be useful for cancer therapy?

Horizon Discovery has been exploring the potential for various aspects of CRISPR/Cas9 technology to provide further validation. Key to this exercise is the development of conditional systems that can establish the biological significance of a target and move beyond mere statistical significance. Our featured speaker will describe the level of knockdown that can be achieved with degron-tagged CRISPR interference (CRISPRi) proteins, how best to deploy dox-inducible Cas9, and various approaches to delete wild-type alleles of genes so as to replace them with inactive alleles that could be applied at scale. Horizon believes that this suite of technology can improve the effectiveness and precision of target validation for its partners.  

This webinar will benefit academic & pharmaceutical researchers in drug discovery, including those who are interested in target validation with in vitro models, and CRISPR/Cas9 technology to provide further validation to de-risk potential druggable targets.

For more information about this complimentary event visit: Better Target Validation for Drug Discovery with CRISPR/Cas9.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com

For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar

Contact:
Nima Rajan
Tel: +1 (416) 977-6555 ext 352
Email: [email protected]

Source: Xtalks

Powered by WPeMatico